Stockreport

IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway [Yahoo! Finance]

Clene Inc.  (CLNN) 
PDF The FDA recommended using neurofilament light chain biomarker analyses to substantiate the drug's efficacy. Clene is a late clinical-stage biopharmaceutical company fo [Read more]